Azizi Miskon

Prof. Dr. Azizi Miskon


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2019 in Nanomaterials
Verified
Journal Article
Open access
PDF file
AMAbdul Mukheem
Abdul Mukheem
Syed ShahabuddinSyed Shahabuddin
Syed Shahabuddin
NANoor Akbar
Noor Akbar
AMAzizi Miskon
Azizi Miskon
NSNorazilawati Muhamad Sarih
Norazilawati Muhamad Sarih
NNNanthini NanthiniSridewi
Nanthini NanthiniSridewi
The present research focused on the fabrication of biocompatible polyhydroxyalkanoate, chitosan, and hexagonal boron nitride incorporated (PHA/Ch-hBN) nanocomposites through a simple solvent casting technique. The fabricated nanocomposites were comprehensively characterized by Fourier transform infrared spectroscope (FT-IR), field emission scanning electroscope (FESEM), and elemental mapping and thermogravimetric analysis (TGA). The antibacterial activity of nanocomposites were investigated through time-kill method against multi drug resistant (MDR) microbes such as methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli (E. coli) K1 strains. In addition, nanocomposites have examined for their host cytotoxicity abilities using a Lactate dehydrogenase (LDH) assay against spontaneously immortalized human keratinocytes (HaCaT) cell lines. The results demonstrated highly significant antibacterial activity against MDR organisms and also significant cell viability as compared to the positive control. The fabricated PHA/Ch-hBN nanocomposite demonstrated effective antimicrobial and biocompatibility properties that would feasibly suit antibacterial and biomedical applications.

26 February 2018 in Military Medical Research
Verified
Journal Article
Open access
PDF file
CUChinedu Cletus Ude
Chinedu Cletus Ude
AMAzizi Miskon
Azizi Miskon
RIRuszymah Bt Hj Idrus
Ruszymah Bt Hj Idrus
MBMuhamad Abu Bakar
Muhamad Abu Bakar
The dynamic nature of modern warfare, including threats and injuries faced by soldiers, necessitates the development of countermeasures that address a wide variety of injuries. Tissue engineering has emerged as a field with the potential to provide contemporary solutions. In this review, discussions focus on the applications of stem cells in tissue engineering to address health risks frequently faced by combatants at war. Human development depends intimately on stem cells, the mysterious precursor to every kind of cell in the body that, with proper instruction, can grow and differentiate into any new tissue or organ. Recent reports have suggested the greater therapeutic effects of the anti-inflammatory, trophic, paracrine and immune-modulatory functions associated with these cells, which induce them to restore normal healing and tissue regeneration by modulating immune reactions, regulating inflammation, and suppressing fibrosis. Therefore, the use of stem cells holds significant promise for the treatment of many battlefield injuries and their complications. These applications include the treatment of injuries to the skin, sensory organs, nervous system tissues, the musculoskeletal system, circulatory/pulmonary tissues and genitals/testicles and of acute radiation syndrome and the development of novel biosensors. The new research developments in these areas suggest that solutions are being developed to reduce critical consequences of wounds and exposures suffered in warfare. Current military applications of stem cell-based therapies are already saving the lives of soldiers who would have died in previous conflicts. Injuries that would have resulted in deaths previously now result in wounds today; similarly, today’s permanent wounds may be reduced to tomorrow’s bad memories with further advances in stem cell-based therapies.

24 March 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Yan Yik LimYan Yik Lim
Yan Yik Lim
AZAhmad Mujahid Ahmad Zaidi
Ahmad Mujahid Ahmad Zaidi
AMAzizi Miskon
Azizi Miskon
Due to its built-up chemoresistance after prolonged usage, the demand for replacing platinum in metal-based drugs (MBD) is rising. The first MBD approved by the FDA for cancer therapy was cisplatin in 1978. Even after nearly four and a half decades of trials, there has been no significant improvement in osteosarcoma (OS) therapy. In fact, many MBD have been developed, but the chemoresistance problem raised by platinum remains unresolved. This motivates us to elucidate the possibilities of the copper and zinc (CuZn) combination to replace platinum in MBD. Thus, the anti-chemoresistance properties of CuZn and their physiological functions for OS therapy are highlighted. Herein, we summarise their chelators, main organic solvents, and ligand functions in their structures that are involved in anti-chemoresistance properties. Through this review, it is rational to discuss their ligands’ roles as biosensors in drug delivery systems. Hereafter, an in-depth understanding of their redox and photoactive function relationships is provided. The disadvantage is that the other functions of biosensors cannot be elaborated on here. As a result, this review is being developed, which is expected to intensify OS drugs with higher cure rates. Nonetheless, this advancement intends to solve the major chemoresistance obstacle towards clinical efficacy.

1 April 2018 in Experimental Gerontology
Verified
Journal Article
Closed access
CUC.C. Ude
C.C. Ude
BSB.S. Shamsul
B.S. Shamsul
MNM.H. Ng
M.H. Ng
HCHui Cheng Chen
Hui Cheng Chen
HOHtwe Ohnmar
Htwe Ohnmar
BRB.H.I. Ruszymah
B.H.I. Ruszymah

27 October 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Yan Yik LimYan Yik Lim
Yan Yik Lim
AZAhmad Mujahid Ahmad Zaidi
Ahmad Mujahid Ahmad Zaidi
AMAzizi Miskon
Azizi Miskon
Medication in arthritis therapies is complex because the inflammatory progression of rheumatoid arthritis (RA) and osteoarthritis (OA) is intertwined and influenced by one another. To address this problem, drug delivery systems (DDS) are composed of four independent exogenous triggers and four dependent endogenous stimuli that are controlled on program and induced on demand, respectively. However, the relationships between the mechanisms of endogenous stimuli and exogenous triggers with pathological alterations remain unclear, which results in a major obstacle in terms of clinical translation. Thus, the rationale for designing a guidance system for these mechanisms via their key irritant biosensors is in high demand. Many approaches have been applied, although successful clinical translations are still rare. Through this review, the status quo in historical development is highlighted in order to discuss the unsolved clinical difficulties such as infiltration, efficacy, drug clearance, and target localisation. Herein, we summarise and discuss the rational compositions of exogenous triggers and endogenous stimuli for programmable therapy. This advanced active pharmaceutical ingredient (API) implanted dose allows for several releases by remote controls for endogenous stimuli during lesion infections. This solves the multiple implantation and local toxic accumulation problems by using these flexible desired releases at the specified sites for arthritis therapies.

22 January 2022 in Journal of Zhejiang University-SCIENCE B
Verified
Journal Article
Closed access
PDF file
HHHaslinda Abdul Hamid
Haslinda Abdul Hamid
VSVahid Hosseinpour Sarmadi
Vahid Hosseinpour Sarmadi
VPVivek Prasad
Vivek Prasad
RRRajesh Ramasamy
Rajesh Ramasamy
AMAzizi Miskon
Azizi Miskon
Mesenchymal stem/stromal cell (MSC)-based therapy has been regarded as one of the most revolutionary breakthroughs in the history of modern medicine owing